ACTRN12611000002987尚未招募4 期
An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- o limit 至 18 Years（—）
- 性别
- All
入选标准
- •An inpatient at the Royal Children's Hospital
- •Diagnosis of constipation as defined by lack of bowel motion for 3 days
- •Chronic opioid treatment (1 week continuous duration)
- •Failed all other standard aperient treatment
- •Vascular access
排除标准
- •Other causes of constipation (eg cow's milk protein intolerance, poor oral intake)
- •Signs and symptoms of bowel obstruction
- •Suspected or diagnosed with delirium
- •Likely to pass away this admission
研究者
相似试验
未知
1 期
An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumorssolid tumorsJPRN-jRCT2080220594Abbott Japan Co., Ltd.
进行中（未招募）
不适用
An open – label clinical trial to study pharmacokinetics (PK) of different levels (0.125 mg, 0,25 mg, 0.5 mg) of pramipexole taken once a day by month in children who can accepte stable pramipesole doses for the treatment of Restless Leg Syndrome (RLS) – A disorder which feel the urge to move the legs to reduce the unpleasant sensatioRestless Legs SyndromeMedDRA version: 14.0Level: PTClassification code 10058920Term: Restless legs syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002774-23-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.36
进行中（未招募）
1 期
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864EUCTR2017-002985-28-BEMerck KGaA148
进行中（未招募）
1 期
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864EUCTR2017-002985-28-DKMerck KGaA148
撤回
不适用
A phase I, open-label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy terminatioNA (healthy volunteers)10010273NL-OMON40897ObsEva SA6